Allergan Finance LLC 8-K 2008
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
May 12, 2008
Date of Report (Date of earliest event reported)
WATSON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
311 Bonnie Circle
Corona, California, 92880
(Address of principal executive offices) (Zip Code)
(Registrants telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
TABLE OF CONTENTS
Effective May 12, 2008, Dr. Allen Chao resigned from the Board of Directors of Watson Pharmaceuticals, Inc. (the Company). The resignation of Dr. Chao was not based on any disagreements between Dr. Chao and the Company relating to the Companys operations, policies or practices.
The Board of Directors appointed Mr. Andrew L. Turner to replace Dr. Chao as Chairman of the Board effective as of May 12, 2008.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.